Replies to post #250573 on Biotech Values

[Mufaso]

Just my sense in listening to the cc. Here was the exchange on that from the transcript:

Q- Joe Pantginis

Okay. Very fair. And then my last question, obviously, this goes into later 2024 and beyond. Are you willing to take any first passes now with regard to pivotal study plans or even designs?

A- Brian Lian

For obesity?

Joe Pantginis

For obesity, for NASH, in general for the company, yes.

Brian Lian

Yes, yes, yes. Yes, with both of these programs, we plan to speak with the FDA following the data analysis. So we'd like to have a Type C meeting with the FDA on the VK2735 program and outline potential next steps there. And then with the NASH program, have an end of Phase 2 meeting. And we know what the guidance is for both indications, but it would be nice to talk with the FDA to learn any recommendations or new comments that they have regarding trial design. But we do have a pretty good idea on what those trials will look like.